Delving into the Latest Updates on HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech) with Synapse

Overview

Basic Info

Drug Type

CAR-NK

Synonyms

EB-DT-CAR-NK(HER2/ROR1)

Target

HER2 x ROR1

Action

modulators

Mechanism

HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators), ROR1 modulators(Inactive tyrosine-protein kinase transmembrane receptor ROR1 modulators)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This Phase 1/2, open-label, biomarker-guided platform study evaluates the safety, tolerability, and preliminary anti-tumor activity of banked allogeneic donor-derived chimeric antigen receptor natural killer (CAR-NK) cells in adults with advanced solid tumors. During screening, tumor antigen profiling is performed using tissue biopsy and/or liquid biopsy (circulating tumor DNA and/or circulating tumor cells).
Participants are assigned to receive either a single-target CAR-NK product (matched to the dominant tumor antigen) or a dual-target CAR-NK product (matched to two co-expressed antigens) to reduce the risk of antigen escape.

Start Date02 Mar 2026

Sponsor / Collaborator

Beijing Biotech

NCT07486089

/ RecruitingPhase 1/2

Phase 1/2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease).

This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.

Start Date02 Feb 2026

Sponsor / Collaborator

Beijing Biotech

100 Clinical Results associated with HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)

Login to view more data

100 Translational Medicine associated with HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)

Login to view more data

100 Patents (Medical) associated with HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)

Login to view more data

100 Deals associated with HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech)

Login to view more data